New research from the University of Cologne suggests inflammation plays a more significant role in small cell lung cancer (SCLC) than previously understood, possibly hindering the body’s immune response and fueling aggressive tumor growth. Published in nature Communications on December 23, 2025, the study details a newly discovered mechanism involving the protein Caspase-8 and a resulting inflammatory response that appears to occur before tumor formation. These findings offer potential new targets for therapies aimed at improving the dismal five-year survival rate for this particularly deadly form of lung cancer, which currently stands at just 5%.
Share on:
12/23/2025 15:05
Inflammation Fuels Aggressive Form of Lung Cancer
Researchers at the University of Cologne have identified a new mechanism that allows one of the most aggressive forms of lung cancer to evade treatment, potentially opening avenues for more effective therapies. The findings were published in “Nature Communications.”
Small cell lung cancer (SCLC) is a particularly aggressive form of the disease, with a five-year survival rate of just 5%. Despite an initial good response to chemotherapy, patients often experience relapse and rapid disease progression. Further research into the biological mechanisms driving SCLC is crucial to extending treatment effectiveness, overcoming relapse, and ultimately improving long-term outcomes for patients. Understanding how this cancer develops and resists treatment is a critical step toward better care.
A research team led by Professor Dr. Silvia von Karstedt (Translational Genomics, Excellence Cluster for Aging Research CECAD and Center for Molecular Medicine Cologne – CMMC) has discovered a novel mechanism contributing to SCLC’s aggressive nature. The study, titled “Lack of Caspase 8 Directs Neuronal Progenitor-like reprogramming and Small Cell Lung Cancer Progression,” appeared in the journal Nature Communications.
Unlike other epithelial carcinomas, SCLC shares characteristics with neuronal cells, including a lack of expression of Caspase-8, a protein involved in programmed cell death (apoptosis) – a process essential for eliminating damaged or mutated cells and maintaining cellular health.
To better mimic human SCLC, the team developed and characterized a new genetically modified mouse model lacking Caspase-8. Using this model, researchers observed that the absence of this protein triggers an unusual chain reaction.
“The lack of Caspase-8 leads to a type of inflammatory cell death called necroptosis, which creates a hostile, inflamed environment even before a tumor fully forms,” explained von Karstedt. “We were also fascinated to find that this pre-tumoral necroptosis can actually promote cancer by conditioning the immune system,” she added. This inflammation suppresses the body’s natural immune response against cancer, preventing immune cells from attacking threats like cancer cells, potentially fostering tumor metastasis.
Surprisingly, the scientists found that this inflammation also causes cancer cells to behave more like immature, neuron-like cells – a state where they can spread more easily and is associated with relapse.
Whether a similar pre-tumoral inflammation occurs in humans remains to be seen. However, these new findings have identified a mechanism that contributes to the aggressiveness and relapse of SCLC patients, with the potential to make future therapies and diagnostic methods more effective in early stages.
The research was funded by the German Research Foundation (DFG) within the Collaborative Research Centre (SFB) 1399 “Mechanisms of Drug Sensitivity and Resistance in Small Cell Bronchial Carcinoma.”
Contact for scientific information:
Professorin Dr. Silvia von Karstedt
Abteilung für Translationale Genomik, Universitätsklinikum Köln
+49 221 478 84340
[email protected]
Original publication:
https://www.nature.com/articles/s41467-025-67142-4
Images
CD45-Färbung von Lungenalveolargewebe in einem new SCLC-Mausmodell. Increased inflammation (CD45 = immune cells, brown) occurs in these mice before tumor development.
Source: Ariadne Androulidaki
Copyright: Universität zu Köln
Criteria of this press release:
Journalists, Scientists and scholars
Biology, Medicine
transregional, national
Research results
German
